• Nebivolol hydrochloride: Practical Assay Workflows

  2026-09-14

  Nebivolol hydrochloride enables selective β1-adrenoceptor interrogation while serving as a useful negative comparator in mTOR inhibitor screens. This workflow combines careful DMSO formulation, receptor-proximal readouts, and orthogonal yeast testing to separate β1-adrenergic effects from nonspecific growth or pathway changes.

• Phalloidin (B7678): F-Actin Workflow Guide

  2026-09-13

  Phalloidin (B7678) is a cyclic heptapeptide toxin used to bind and stabilize filamentous actin for fixed-cell, permeabilized-sample, tissue-section, and cell-free cytoskeleton visualization. It is not appropriate for live-cell imaging, reversible actin-binding studies, or direct measurement of normal cytoskeletal dynamics.

• IWR-1-endo: Practical Wnt Signaling Inhibition

  2026-09-12

  IWR-1-endo provides a chemically tunable way to suppress Wnt/β-catenin activity in colorectal cancer, regeneration, and stem-cell assays. This workflow-focused guide covers stock preparation, dose-response design, single-cell integration, and troubleshooting for more reproducible pathway studies.

• Digoxin Beyond the Pump: A Translational Playbook

  2026-09-11

  Digoxin is more than a canonical Na+/K+ ATPase pump inhibitor. This thought-leadership guide connects cardiac ion handling, HIF-1α biology, antiviral screening, and translational decision-making while defining the experimental controls needed to interpret Digoxin across disease models.

• BNNC: Hypoxia-Activated Cyclin K Degradation

  2026-09-11

  The reference study introduces BNNC, a hypoxia-activated photomolecular glue designed to release the Cyclin K degrader (R)-CR8 together with the phototherapeutic agent BSS-Et in tumor-like conditions. Its combination of tumor-selective activation, Cyclin K degradation, and phototherapy enhanced DNA damage and apoptosis in breast cancer models while producing tumor growth inhibition with favorable preliminary safety findings.

• CP-673451: A PDGFR Assay Design Guide

  2026-09-10

  CP-673451 is a selective PDGFRα/β inhibitor whose value extends beyond nanomolar potency. This guide shows how to connect biochemical selectivity, PDGFR-β phosphorylation, angiogenesis inhibition assay design, ATRX biology, and xenograft interpretation without confusing target engagement with antitumor efficacy.

• Diuron-Induced Acute Kidney Injury: Study Insights

  2026-09-10

  This 2025 study integrates network toxicology, molecular docking, transcriptomic validation, and HK-2 cell experiments to investigate how Diuron may cause acute kidney injury. Its results prioritize JAK2/STAT1 signaling as a mechanistic pathway while defining the limits of computational and in vitro evidence for environmental toxicology.

• BMS-777607: A Practical c-Met Inhibitor Guide

  2026-09-09

  BMS-777607 is a selective c-Met inhibitor for dissecting MET-family signaling in cancer metastasis models and exploratory stem-cell differentiation assays. This guide separates validated oncology use cases from emerging hiPSC platelet applications, with practical dosing, controls, and troubleshooting strategies.

• CP-673451 and the Next Logic of PDGFR Translation

  2026-09-09

  CP-673451 offers a focused way to connect PDGFR biology with translational decision-making. This thought-leadership article examines how its ATP-competitive selectivity can clarify receptor phosphorylation, angiogenesis, and tumor response while incorporating ATRX status into glioma research. It also provides an assay-centered framework, practical protocol parameters, competitive context, and guardrails for interpreting xenograft findings without overstating preclinical evidence.

• (-)-Blebbistatin for Mechanobiology Workflows

  2026-09-08

  Use (-)-Blebbistatin to separate cell-generated traction from externally applied shear in mechanotransduction, cytoskeletal, and contractility assays. Its reversible non-muscle myosin II inhibition adds a practical perturbation layer to studies of GABAB receptor activation, astrocyte remodeling, migration, and actomyosin-dependent mechanics.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-09-08

  A 2025 GeroScience study engineered drug-sensitized Saccharomyces cerevisiae strains to expose TOR-dependent growth inhibition at substantially lower concentrations than wild-type yeast. The platform improved detection of established TOR inhibitors, identified aminophylline as a TOR1-dependent growth inhibitor, and provided no evidence that the tested cardiovascular comparator inhibited TOR in this model.

• NVP-BGJ398 phosphate: FGFR Assay Workflows

  2026-09-07

  NVP-BGJ398 phosphate enables genotype-aware inhibition of FGFR1–3 signaling across cancer and skeletal disease models. This guide connects pathway assays, chondrocyte phenotyping, and troubleshooting strategies to help researchers distinguish target engagement from nonspecific toxicity.

• Epacadostat: A Functional IDO1 Assay Strategy

  2026-09-07

  Epacadostat (INCB024360) links nanomolar IDO1 inhibition to functional immune-readout design. This guide explains how to integrate biochemical, cellular, and whole-blood assays while avoiding overinterpretation of cytokine data.

• Prion-Based Mutagenesis and Rapid Adaptation

  2026-09-05

  A 2026 Cell study shows that prion-like protein self-assembly can reversibly and heritably tune DNA repair and recombination, changing mutation patterns and adaptive trajectories in yeast. Its cross-species experiments connect protein-based epigenetic memory with accelerated drug resistance and identify prion-maintenance machinery as a potential control point.

• Cediranib (AZD2171) for Better Cancer Assays

  2026-09-04

  Cediranib (AZD2171) helps separate VEGFR target engagement from downstream growth and death phenotypes in angiogenesis and cancer research. This workflow combines time-resolved signaling, endothelial assays, and orthogonal viability measurements to produce more interpretable responses than a single endpoint.

8432 records 1/563 page Next 12345 下5页 Last page